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Abstract
Background: Post-transplant lymphoproliferative disease is a recognized complication following solid organ
transplantation. This is usually a B cell disease and frequently associated with Epstein Barr virus infection, although T cell
PTLD can occur. T cell PTLD is usually a monomorphic, lymphomatous disease associated with an adverse prognosis.
Case report: We report a 52 year old male pre-emptive renal transplant recipient who developed severe diarrhea with
weight loss following intensification of his immunosuppression due to antibody mediated rejection 3 years after
transplantation. Duodenal biopsy demonstrated monoclonal CD8+ T cell duodenitis leading to increased intraepithlieal
lymphocytes and sub-total villous atrophy mimicking coeliac disease. Coeliac disease was excluded by negative anti-
tissue transglutaminase antibody, HLA-DQ2 and HLA-DQ8 testing. There was no evidence of lymphoma either on
biopsy or CT enterography and no FDG avid disease on PET. Symptoms did not improve with reduction of
immunosuppression, but resolved fully on complete withdrawal of treatment. The transplant failed and he was
established on dialysis. The diagnosis was early PTLD.
Conclusions: Oesophagogastroduodenoscopy with small bowel biopsies is a useful investigation for determining the
cause of diarrhoea in renal transplant patients when more common causes have been excluded. This is the first report
that we are aware of clonal T cell PTLD mimicking coeliac disease which only resolved after complete withdrawal of
immunosuppression. As treatments for lymphoma are aggressive they are only initiated in the malignant phase and
management of early stage PTLD is to minimise risk of progression by reducing immunosuppression. Any plans to
retransplant will have to take into consideration the possibility that PTLD will recur.
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Background
The term post-transplant lymphoproliferative disease
(PTLD) was first introduced in 1984 [1] and describes a
range of pathologies occurring as a consequence of im-
munosuppression from reactive lymphoid hyperplasia to
lymphoma. The incidence of PTLD after kidney trans-
plantation is ~ 3% [2] and is increased by more intensive
immunosuppression. PTLD can be either monomorphic
or polymorphic and B cell PTLD is frequently associated
with Epstein Barr virus (EBV) infection or reactivation
with cells showing a distinct pattern of EBV antigen ex-
pression. T cell PTLD is less common and accounts for
4% of cases in the early post-transplant period and 15%
of cases of late PTLD (> 2 years since transplant) [3]. T
cell PTLD is a heterogenous group of diseases which are
only associated with EBV infection in around 30% of
cases [4, 5]. These are most commonly monomorphic,
although polymorphic disease is described, and associ-
ated with a poor prognosis.
In patients with renal allografts there are many poten-
tial causes of persistent diarrhoea, including those asso-
ciated with immunosuppression, such as the side effects
of mycophenolic acid and intestinal PTLD, and those
that cause diarrhoea in non-immunosuppressed patients.
Coeliac disease affects around 1% of adults, can affect
transplant recipients and should be included in the list
of differential diagnoses. Coeliac disease, due to an im-
mune response to dietary gluten, typically causes gastro-
intestinal symptoms, but is also associated with a range
of non-GI manifestations. Autoantibodies to tissue
transglutaminase (anti-TTG) are found in 95% of pa-
tients with coeliac disease but duodenal biopsy remains
the cornerstone of diagnosis. Typically, this shows evi-
dence of a lymphocytic infiltrate, crypt hyperplasia, in-
flammation of the lamina propria and villous atrophy
[6]. Treatment is with a gluten free diet, although rarely
refractory disease is recognised.
We report a patient who developed severe diarrhoea with
a T cell rich lymphocytic duodenal infiltrate, mimicking
coeliac disease, but due to monoclonal T cell PTLD. The
disease resolved on withdrawal of immunosuppression.
Case presentation
A 52 year old man received a pre-emptive renal trans-
plant from his wife for the treatment of end stage renal
disease due to autosomal dominant polycystic kidney
disease (HLA mismatch 1–1-1, CMV mismatch D+/R-,
EBV IgG not detected). He received alemtuzumab at in-
duction (30 mg subcutanously on day 0 and day 1)
followed by maintenance immunosuppression with ta-
crolimus, mycophenylate mofetil (MMF) and prednisol-
one. As he was enrolled in a clinical trial, the use of
alemtuzumab for induction was determined by the arm
he was randomised to. He continued on tacrolimus
before being randomised at 6 months to switch to siroli-
mus as part of the clinical trial [7]. A year later he had
to leave the study as he was undergoing incisional hernia
repair so returned to tacrolimus-based
immunosuppression.
Three years after transplantation renal function started
to decline. Chronic antibody mediated rejection (CAMR)
was found on transplant renal biopsy and new donor
specific antibodies against HLA class II were detected.
Tacrolimus and MMF doses were increased and he
restarted on 5mg prednisolone. The daily total tacroli-
mus dose was increased from 3mg to 5 mg with levels
rising from 5.4 μg/L to 7.0 μg/L and MMF daily dose
was doubled from 1000 mg to 2000 mg. A month after
this change he presented to primary care having passed
frank blood in his stool and with a one week history of
abdominal pain and faecal urgency. In response to these
symptoms MMF was switched to mycophenolic acid,
but the diarrhoea continued and he was admitted on
two occasions due to worsening renal function.
Five months after biopsy confirmed CAMR, rituximab
was started at a dose of 200mg with a planned frequency of
every 6–8months and mycophenolic acid was withdrawn.
Although rectal bleeding resolved the diarrhoea continued
and he experienced 4 kg of weight loss over 2months with
an overall weight loss of around 14 kg over a year.
Investigations for the cause of his diarrhoea included
CMV and EBV PCR and stool culture which were all
negative at initial presentation. Faecal elastase was also
normal and gastric parietal cell and enterocyte antibody
testing was negative. Flexisigmoidoscopy showed non-
bleeding haemorrhoids and colonoscopy was normal.
Radionucleotide SeHCAT bile study to assess for bile
acid malabsorption was also normal. Imaging studies in-
cluding PET, CT thorax-abdomen-pelvis, CT enterogra-
phy and MRI small bowel showed no evidence of
malignancy or other bowel pathology.
EBV DNA was not detectable in serum by PCR at the on-
set of diarrhoea and EBV IgG remained negative. However,
6 weeks after the onset of diarrhoea EBV DNA was de-
tected at titres of 1612 IU/ml and then fluctuated between
not detected and 6770 IU/ml for the duration of his diar-
rhoea. EBV DNA was detected at low levels (< 1000 IU/ml)
when tacrolimus dose was further reduced (levels in the re-
gion of 3.8 μg/L). Given symptomatic improvement EBV
DNA PCR was not repeated on complete withdrawal of
immunosuppression.
Creon was started under gastroenterology advice and lo-
peramide was prescribed for symptomatic relief. Oesopha-
gogastroduodenoscopy (OGD) was performed to investigate
loss of appetite and further weight loss. Biopsies from the
duodenum identified moderate lymphocytic duodenitis with
mucosal damage as evidenced by shortening villi, in keeping
with coeliac disease (Fig. 1). However, diarrhoea was
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unresponsive to a gluten free diet and he was nega-
tive for antibodies to tissue transglutaminase and
HLA DQ2 and DQ8.
Repeat OGD after 6 months of gluten free diet identi-
fied a clonal T-cell population. The intra-epithelial T-
cells had normal immunohistochemistry, in that they
expressed the antigens CD3 and CD8, but reproducible
clonal T-cell receptor (TCR) beta and TCR gamma rear-
rangements were detected using a multiplex PCR assay
[8]. Immunoglobulin heavy chain gene rearrangements
were polyclonal, excluding clonal B cell proliferation.
There was no evidence of lymphoma either on biopsy or
CT enterography and no FDG avid disease on PET.
After further reductions in tacrolimus repeat duodenal
biopsies found a persistence of a clonal T cell population
and mucosal damage with subtotal villous atrophy and a
suggestion of crypt hyperplasia. Almost 3 years since the
episode of CAMR and onset of diarrhoea all immuno-
suppression was withdrawn and peritoneal dialysis was
commenced. The diarrhoea improved within days of
stopping immunosuppression and the patient remains
well on dialysis with no diarrhoea and he has success-
fully regained the weight he lost when unwell.
Discussion and conclusions
We report duodenitis with seronegative villous atrophy
and non-malignant clonal T-cell proliferation secondary
to immunosuppression in a renal transplant recipient.
The diagnosis of early PTLD is supported by full reso-
lution of symptoms on withdrawal of immunosuppres-
sion. As far as we are aware there are no other case
reports describing this set of findings.
Lymphoma, including PTLD, is a recognised complica-
tion following solid organ transplantation. In this case, the
clonal T cell proliferation was pre-malignant with a high
risk of progressing to enteropathy associated T cell lymph-
oma (EATL). Our patient had a high immunosuppressive
burden at the time of presentation as his therapy had been
increased to manage CAMR and he had received alemtu-
zumab at induction. As a lymphocyte-depleting agent,
alemtuzumab causes prolonged immunosuppression with
full B cell recovery taking 12months and T cells reaching
50% of normal levels at 36months [9]. Treatments for
lymphoma are aggressive so they are only initiated in the
malignant phase and management of early stage PTLD is
to minimise risk of progression by reducing immunosup-
pression. Histological findings in lymphoma are variable
but can include morphological evidence of mucosal dam-
age by an aberrant lymphocytic population with an abnor-
mal lymphocytic phenotype and loss of at least one of the
T-cell antigens. On imaging the presence of FDG avid le-
sions on PET is characteristic [10]. Neither of these fea-
tures occurred in our case.
Other differentials for seronegative villous atrophy in-
clude coeliac disease and autoimmune enteropathy.
Autoimmune enteropathy is a rare disease, more com-
mon in children, and the diagnosis was not supported
here as all antibody testing was negative and the condi-
tion is treated with immunosuppression [11].
Coeliac disease that is non-responsive to a gluten free
diet and has clonal T-cells on biopsy is termed refractory
coeliac disease type II (RCD II). In this condition intrae-
pithelial lymphocytes are CD3+ and CD8- so are pheno-
typically abnormal and the associated increased risk of
Fig. 1 Duodenal mucosa showing subtotal villous atrophy, crypt hyperplasia and increased intraepithelial lymphocytes on (a) H&E staining.
Immunohistochemical staining (shown in brown) of duodenal mucosa for (b) TCR, (c) CD8 and (d) CD3. All images × 10 magnification
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transformation to EATL would encourage a reduction in
immunosuppression [12]. Anti-TTG testing is important
for making the diagnosis of coeliac disease with sensitiv-
ity of > 90% and specificity of > 95%. TTG is an enzyme
that removes an amide group from gluten peptides to in-
crease their binding to HLA-DQ2 and DQ8 on antigen
presenting cells, stimulating an inflammatory response.
HLA-DQ2 and DQ8 are strongly associated with coeliac
disease as 95% of those with the condition are positive
for HLA-DQ2 and the other 5% positive for HLA-DQ8
but 30–40% of healthy individuals will also be positive
for one of these alleles. HLA testing is useful to exclude
coeliac disease as the negative predictive value ap-
proaches 100%. We can be confident that our case was
not coeliac disease as he was negative for anti-TTG and
HLA-DQ2/DQ8 [13, 14].
Our patient had complete resolution of his symptoms
following withdrawal of immunosuppression. Duodenal
biopsies have not been repeated, but the assumption is
that the duodenitis and villous atrophy will have re-
solved, mirroring the improvement in symptoms. We do
not know whether the T cell clone has been completely
destroyed or is now controlled and therefore cannot pre-
dict whether the disease will recur if immunosuppres-
sion is reintroduced. Patients have been retransplanted
after the successful treatment of PTLD [15, 16] but any
plans for retransplanting this patient must take into ac-
count the possibility that this will recur.
Clonal T cell PTLD is a rare cause of severe diarrhoea
in renal transplant recipients. Clinically, it mimics
coeliac disease and once more common causes have
been excluded, an OGD with small bowel biopsies and
immunohistochemistry can be done to look for the
clonal T cell population specific for T cell PTLD. As
treatment involves withdrawal of immunosuppression
there will be implications for the current graft and it
may be necessary to trial immunosuppressive drugs for
suitable options before considering re-transplantation.
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